MedPath

Can the sensitization profile towards hazelnut, peanut and birch pollen be used to predict the severity of clinical symptoms of hazelnut allergy in both children and adults?

Completed
Conditions
food allergy
hazelnut allergy
10001708
Registration Number
NL-OMON35609
Lead Sponsor
niversitair Medisch Centrum
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Not specified
Target Recruitment
176
Inclusion Criteria

children and adults with a hazelnut sensitization

Exclusion Criteria

congenital/aqcuired immunodeficiency
lymphoproliferative disease
systemic immunosuppression
insufficient knowledge of Dutch language
children from 3-6 years will be excluded from genetic research

Study & Design

Study Type
Observational invasive
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
<p>Based on literature and preliminary data, four determinants are identified,<br /><br>which we think are (most) predictive for the severity of the symptoms of<br /><br>hazelnut allergy. The determinants are: Cor a 1, Cor a 8, Cor a 9 and oleosin.<br /><br>First, the predictive value of each determinant will be assessed using<br /><br>univariate analysis. Second, a multivariable logistic regression model will be<br /><br>build starting with the strongest predictor (based on the relative risk<br /><br>obtained from univariate analysis).<br /><br>To make the prediction model applicable for clinical practice, a prediction<br /><br>rule will be made and for the different possible scores on the prediction rule<br /><br>(or categories of the score), we will present the probability of having severe<br /><br>symptoms of hazelnut allergy.</p><br>
Secondary Outcome Measures
NameTimeMethod
<p>The analysis of IgE and T cell cross-reactivity concerns a secondary analysis<br /><br>to define potential mechanisms responsible for the difference in clinical<br /><br>severity of symptoms. We determine whether there are genetic associations by<br /><br>analysing these polymorfisms.</p><br>
© Copyright 2025. All Rights Reserved by MedPath